Polymyxin B Injection

Polymyxin B Injection

  • Medicine name- Polykris
  • API- Polymyxin-B
  • Packaging- 1 Single-dose vial
  • Strength- 500000 IU
  • Manufactured by-  Ikris Pharma Network
Get an Enquiry
Category: Tags: ,

Description

Patients with the following infections, when brought on by susceptible strains of the specified aerobic gram-negative bacteria, can be treated with Polymyxin- B injection:

  • Urinary tract infections: Pseudomonas aeruginosa and Escherichia coli are the culprits.
  • Pseudomonas aeruginosa, Enterobacter aerogenes (previously known as Aerobacter), and Klebsiella pneumonia are the three main causes of bloodstream infections.
  • Meningeal infections: Pseudomonas aeruginosa is the culprit.
  • Pseudomonas aeruginosa is the cause of eye infections in the cornea and subconjunctival.

Dosage and Side Effects

Only hospitalized patients may get the required dosage of Polymyxin B Injection intravenously, intramuscularly, or intrathecally, under the continual observation of a medical practitioner. The daily dosage of polymyxin B shouldn’t be more than 200 mg or 2.5 mg/kg.

The negative effects of polymyxin B that are most frequently reported are urticaria, neurotoxicity, discomfort at the injection site, and electrolyte imbalance.

Warning and Precautions

  • Therapy involving Polymyxin B 500,000 IU is not recommended for individuals with prior hypersensitivity reactions to it.
  • Polymyxin B sulfate Injection, if used intravenously, intramuscularly, or intrathecally, should be reserved for hospitalized patients under close monitoring for kidney function and neurological symptoms.
  • It should only be used to treat or prevent infections caused by susceptible bacteria to prevent drug-resistant bacterial development and maintain the effectiveness of the medication.
  • Patients with myasthenia gravis should avoid using Polymyxin-B Injection.
  • Regular assessment of renal function is essential before and during treatment due to the nephrotoxic effects of Polymyxin-B Injection.
  • Extreme caution is advised when using Polymyxin-B sulfate injection in patients with porphyria.
  • Use during pregnancy is restricted and should be considered only if the benefits to the mother outweigh potential risks to the fetus.

FAQ's

What does Polymyxin-B treat?

It’s effective against specific gram-negative bacteria causing infections like urinary tract infections, bloodstream infections, meningeal infections, and eye infections in the cornea and subconjunctiva.

How is Polymyxin-B administered?

Typically administered intravenously, intramuscularly, or intrathecally to hospitalized patients under strict medical supervision. The daily dosage should not exceed 200 mg or 2.5 mg/kg.

What are the common side effects of Polymyxin-B?

Frequently reported side effects include urticaria, neurotoxicity, discomfort at the injection site, and electrolyte imbalance.

Are there any precautions for using Polymyxin-B?

It’s not advisable for individuals with prior hypersensitivity reactions. It should be strictly reserved for treating susceptible bacterial infections to prevent drug resistance. Patients with myasthenia gravis should avoid it, and kidney function needs regular monitoring due to potential kidney-related issues.

Is Polymyxin B FDA approved?

Yes, Polymyxin B and its classmate, Polymyxin E (colistin), are FDA-approved for treating serious drug-resistant gram-negative bacterial infections, particularly those caused by Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.

Related products